Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Dexter

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Neuroscience Letters|December 24, 2017
Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibitionIan F Harrison, Andrew D Smith, David T Dexter
Neuroreport|February 22, 2008
Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's modelAnthony C Vernon, Martin J Croucher, David T Dexter
Frontiers in Bioscience (Scholar Edition)|May 12, 2015
Ageing, neuroinflammation and neurodegenerationRoberta J Ward, David T Dexter, Robert R Crichton
Progress in Neurobiology|May 17, 2008
Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agentsRoberta J Ward, Frédéric Lallemand, Philippe de Witte, et al.
Brain : a Journal of Neurology|June 18, 2013
Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteinsMichael J Hurley, Bianca Brandon, Steve M Gentleman, et al.
British Journal of Pharmacology|June 5, 2015
Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factorsIan F Harrison, William R Crum, Anthony C Vernon, et al.
International Journal of Molecular Sciences|April 3, 2021
Is Chelation Therapy a Potential Treatment for Parkinson's Disease?Roberta J Ward, David T Dexter, Antonio Martin-Bastida, et al.
Journal of Neurochemistry|November 23, 2006
Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibitionSimon McArthur, Hilary E Murray, Alihusein Dhankot, et al.
Plos Medicine|July 22, 2015
Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort StudyRuth Brauer, Krishnan Bhaskaran, Nishi Chaturvedi, et al.
NPJ Parkinson'S Disease|July 27, 2023
Neuroprotective role for RORA in Parkinson's disease revealed by analysis of post-mortem brain and a dopaminergic cell lineFelwah S Al-Zaid, Michael J Hurley, David T Dexter, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Neuroscience Letters|December 24, 2017
Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibitionIan F Harrison, Andrew D Smith, David T Dexter
Neuroreport|February 22, 2008
Additive neuroprotection by metabotropic glutamate receptor subtype-selective ligands in a rat Parkinson's modelAnthony C Vernon, Martin J Croucher, David T Dexter
Frontiers in Bioscience (Scholar Edition)|May 12, 2015
Ageing, neuroinflammation and neurodegenerationRoberta J Ward, David T Dexter, Robert R Crichton
Progress in Neurobiology|May 17, 2008
Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agentsRoberta J Ward, Frédéric Lallemand, Philippe de Witte, et al.
Brain : a Journal of Neurology|June 18, 2013
Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteinsMichael J Hurley, Bianca Brandon, Steve M Gentleman, et al.
British Journal of Pharmacology|June 5, 2015
Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factorsIan F Harrison, William R Crum, Anthony C Vernon, et al.
International Journal of Molecular Sciences|April 3, 2021
Is Chelation Therapy a Potential Treatment for Parkinson's Disease?Roberta J Ward, David T Dexter, Antonio Martin-Bastida, et al.
Journal of Neurochemistry|November 23, 2006
Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibitionSimon McArthur, Hilary E Murray, Alihusein Dhankot, et al.
Plos Medicine|July 22, 2015
Glitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort StudyRuth Brauer, Krishnan Bhaskaran, Nishi Chaturvedi, et al.
NPJ Parkinson'S Disease|July 27, 2023
Neuroprotective role for RORA in Parkinson's disease revealed by analysis of post-mortem brain and a dopaminergic cell lineFelwah S Al-Zaid, Michael J Hurley, David T Dexter, et al.
Pageof 7